A detailed history of Versant Capital Management, Inc transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 14 shares of CRL stock, worth $2,550. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14
Previous 57 75.44%
Holding current value
$2,550
Previous $11,000 81.82%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

SELL
$187.96 - $245.29 $8,082 - $10,547
-43 Reduced 75.44%
14 $2,000
Q1 2024

Apr 03, 2024

BUY
$203.52 - $273.43 $7,733 - $10,390
38 Added 200.0%
57 $15,000
Q4 2023

Jan 08, 2024

SELL
$164.52 - $238.84 $2,138 - $3,104
-13 Reduced 40.63%
19 $4,000
Q1 2023

Apr 10, 2023

BUY
$191.89 - $259.92 $3,454 - $4,678
18 Added 128.57%
32 $6,000
Q1 2020

Apr 17, 2020

SELL
$98.9 - $178.34 $1,285 - $2,318
-13 Reduced 48.15%
14 $1,000
Q4 2019

Jan 28, 2020

SELL
$126.05 - $152.76 $4,033 - $4,888
-32 Reduced 54.24%
27 $4,000
Q2 2019

Jul 16, 2019

SELL
$123.4 - $148.55 $863 - $1,039
-7 Reduced 10.61%
59 $8,000
Q1 2019

Apr 23, 2019

SELL
$104.82 - $146.73 $5,974 - $8,363
-57 Reduced 86.36%
9 $9,000
Q1 2019

Apr 23, 2019

BUY
$104.82 - $146.73 $5,974 - $8,363
57 Added 633.33%
66 $9,000
Q1 2018

Apr 19, 2018

SELL
$98.19 - $115.2 $687 - $806
-7 Reduced 9.59%
66 $7,000
Q3 2017

Apr 23, 2018

SELL
$96.72 - $109.26 $483 - $546
-5 Reduced 6.41%
73 $7,000
Q1 2017

Apr 23, 2018

SELL
N/A
-1 Reduced 1.27%
78 $7,000
Q4 2016

Apr 23, 2018

SELL
N/A
-27 Reduced 25.47%
79 $6,000
Q3 2016

Apr 23, 2018

SELL
N/A
-4 Reduced 3.64%
106 $8,000
Q4 2015

Apr 23, 2018

BUY
N/A
110
110 $8,000

Others Institutions Holding CRL

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.


  • Ticker CRL
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 50,863,300
  • Market Cap $9.26B
  • Description
  • Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...
More about CRL
Track This Portfolio

Track Versant Capital Management, Inc Portfolio

Follow Versant Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Versant Capital Management, Inc with notifications on news.